Dividends CalendarEarnings Calendar

UMRX | Unum Therapeutics Inc.

Unum Therapeutics Inc.

Company profile

  • Industry: Biotechnology
  • Sector: Healthcare
  • Headquarters:   Massachusetts, United States
  • Number of employees::   29

Company profile

Unum Therapeutics is a biopharmaceutical company focused on developing curative cell therapies to treat patients with advanced cancers. Unum’s novel proprietary technology called Bolt-On Chimeric Receptor (BOXR) is designed to improve the functionality of engineered T cells by discovering and incorporating a “bolt-on” transgene into a patients’ engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Unum’s BOXR1030, the first preclinical product candidate to emerge from the BOXR platform, is composed of a GPC3-targeted CAR T cell and a “bolt-on” enzyme called glutamic-oxaloacetic transaminase 2 (GOT2) that aims to improve T cell function in the solid tumor microenvironment through enhanced metabolism. GOT2 plays a central metabolic role by linking multiple pathways involved in biosynthesis and cellular energy production.


    200 Cambridge Park Drive
    Suite 3100
    Cambridge, MA 02140
    United States

      Jump to (Finance sites)

      Their Official Profiles 


      Other stocks 

      snap jnj t s orcl hd dri kmx ctas kr agro keys 

      Support this project

      If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
      More features coming soon :)

      Social Media 

      Recommended Books

      The Internet of Money
      Buy on Amazon

      While many books explain the how of bitcoin, The Internet of Money delves into the why of bitcoin. Acclaimed information-security expert and author of Mastering Bitcoin, Andreas M. Antonopoulos examines and contextualizes the significance of bitcoin through a series of essays spanning the exhilarating maturation of this technology.